Leica Biosystems is a global leader in workflow solutions and automation designed to help pathology laboratories and researchers shorten the time between biopsy and diagnosis. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s goal is to make diagnosis within 24 hours of a biopsy possible.
Leica Biosystems is trusted by 100 percent of the top 50 U.S. cancer centers, according to U.S. News & World Report. Founded in 1989, the company joined Danaher in 2006 and continues to make significant investments in new product development. Recent innovations have focused on digital pathology, with the launch of the Aperio VERSA and LV1 scanners and histology equipment, introducing a next-generation H&E stainer.